In conclusion, LCT appears to provide additional survival benefits for NSCLC patients with ORD after effective PD-1/PD-L1 inhibitors-based therapy, especially for patients with 1–2 residual lesions, high PD-L1 expression or who receive LCT for all residual diseases. Here, CD274 is linked to non-small cell lung carcinoma.